1st Quarter - Report

MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY for MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY

Firm
Client
Income
—
Expenses
$515,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Incentives for health information technology, proposed regulation of medical software, proposals to promote healthcare interoperability, and other healthcare policy issues. S. 1101, MEDTECH Act; S. 2141, Trust IT Act.

LobbyistCovered position, as disclosed
JOSEPH M GANLEY —
PETER SLONE New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1101 (114th), S. 2141 (114th)

Veterans VET

Education regarding existing Department of Veterans' Affairs Pharmaceutical Prime Vendor Contract

LobbyistCovered position, as disclosed
JOSEPH M GANLEY —
PETER SLONE New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Proposals to repeal LIFO

LobbyistCovered position, as disclosed
JOSEPH M GANLEY —
PETER SLONE New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Physician and pharmacy reimbursement issues and implementation of the Affordable Care Act. H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015 Medicare Part B Drug Payment Model Proposed Rule

LobbyistCovered position, as disclosed
MATT BROW —
JOSEPH M GANLEY —
BEN JONES —
KATIE JONES New —
KEAGAN R LENIHAN —
PETER SLONE New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1314 (114th), H.R. 2895 (114th), H.R. 1416 (114th), H.R. 696 (114th)

Pharmacy PHA

Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion, H.R. 471 "Ensuring Patient Access and Effective Drug Enforcement Act of 2015", S. 483 "Ensuring Patient Access and Effective Drug Enforcement Act of 2015", S.524 "Comprehensive Addiction and Recovery Act of 2016".

LobbyistCovered position, as disclosed
JOSEPH M GANLEY —
PETER SLONE New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 483 (114th), H.R. 471 (114th), S. 524 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.